https://www.selleckchem.com/products/gsk621.html
3 (6.3), respectively, which represents the dose saving to healthy tissues. The maximum percentage differences between DVH curve of IsoAid and IrSeed seeds was about 8%. Our simulation results show that although new model of the I brachytherapy source having a slightly larger dimension than IAI-125A, it can be used for eye melanoma treatment because the COMS eye plaque loaded with IrSeed-125 could produce similar results to the IsoAid seeds, which is applicable for clinical plaque brachytherapy for uveal melanoma. Our simulation results
Like
Comment
Share
